PDF: Lebrikizumab for Moderate-to-Severe Atopic Dermatitis

PDF Download: Lebrikizumab is a new IL-13 targeting monoclonal antibody approved for moderate-to-severe atopic dermatitis in patients 12+ years. Learn about clinical trial efficacy, safety data, dosing, and how it compares to other AD biologics like dupilumab and tralokinumab.
Read online:
Lebrikizumab for Moderate-to-Severe Atopic Dermatitis